Kevin Bays, MD
Psychiatry · Louisville, KYNPI 1386695831
Payments from drug & device makers
Across 563 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Bausch Health US, LLC$823
- Vanda Pharmaceuticals Inc.$805
- Lundbeck LLC$761
- Teva Pharmaceuticals USA, Inc.$687
- Sunovion Pharmaceuticals Inc.$613
- plus $3K from 22 others
What the payments were for
- Food & beverage$9,092100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 146 | $1,925 |
| Bausch Health US, LLC | 64 | $823 |
| Vanda Pharmaceuticals Inc. | 36 | $805 |
| Lundbeck LLC | 41 | $761 |
| Teva Pharmaceuticals USA, Inc. | 44 | $687 |
| Sunovion Pharmaceuticals Inc. | 35 | $613 |
| Neuronetics, Inc. | 11 | $544 |
| Corium, LLC | 38 | $509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $316 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $283 |
| Otsuka America Pharmaceutical, Inc. | 16 | $261 |
| Alkermes, Inc. | 13 | $232 |
| Tris Pharma Inc | 13 | $228 |
| Johnson & Johnson | 13 | $215 |
| Ironshore Pharmaceuticals Inc. | 9 | $153 |
| Neos Therapeutics, LP | 9 | $121 |
| Idorsia Pharmaceuticals US Inc | 6 | $96 |
| Adlon Therapeutics L.p. | 6 | $83 |
| Eisai Inc. | 5 | $69 |
| Axsome Therapeutics, Inc. | 3 | $65 |
| Shire North American Group Inc | 4 | $56 |
| Noven Therapeutics, LLC | 3 | $53 |
| Avanir Pharmaceuticals, Inc. | 3 | $53 |
| Tempus AI, Inc | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 3 | $36 |
| Merck | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Indivior Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,092 in reported general payments places this provider in the 90th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $99,830 |
| Invega SustennaPaliperidone Palmitate | 25 | $84,755 |
| VraylarCariprazine Hcl | 28 | $44,997 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 138 | $11,103 |
| TrintellixVortioxetine Hydrobromide | 21 | $9,783 |
| SaphrisAsenapine Maleate | 16 | $9,371 |
| Vilazodone Hcl | 96 | $8,083 |
| FetzimaLevomilnacipran Hcl | 13 | $6,352 |
| Lisdexamfetamine Dimesylate | 23 | $4,413 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 66 | $3,435 |
| Bupropion XlBupropion Hcl | 121 | $3,022 |
| Fluoxetine Hcl | 95 | $2,731 |
| Olanzapine | 70 | $2,649 |
| Zolpidem Tartrate ErZolpidem Tartrate | 65 | $2,430 |
| Duloxetine Hcl | 153 | $2,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $215 | $84,75525 claims |
| AbbVieVraylar, Saphris, Fetzima | $1,925 | $60,71957 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $316 | $9,78321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Louisville
- Rifaat El-MallakhLouisville$1.7M
- Robert StewartLouisville$651K
- Ali FarooquiLouisville$393K
- Stephanie HallLouisville$106K
- Kelly ClarkLouisville$14K
- Michael HarrisLouisville$13K
- Yelena VaninaLouisville$12K
- Mohamed KhodeirLouisville$9K
- Terry HaganLouisville$8K
- Ronald McGavicLouisville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.